Edge Therapeutics, a US-based biopharmaceutical company incubated at the New Jersey Institute of Technology, has raised $18m in its series C round. Investment bank Maxim Group was the placement agent and financial adviser for the offering, which will fund a phase II study of its lead product candidate, EG-1962 (nimodipine microparticles), for the prevention of…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
